Ongoing Phase II Trial: Hepatitis C Virus Undetectable in Patients | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Sin City’s Veiled Threat to Hepatitis C

Back to News Homepage
Next

3 Hep C Treatment Side Effects Aided by Probiotics

Ongoing Phase II Trial: Hepatitis C Virus Undetectable in Patients

The Editors at Hepatitis Central
October 9, 2013

Print this page

Boehringer Ingelheim, a leading pharmaceutical company, along with Presidio Pharmaceuticals, has developed a 12-week interferon-free program with promising results.

Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial

08 October 2013

Ingelheim, Germany (Business Wire (Business Wire India))

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C.1 The poster presentation will be on Monday 4 November.

This ongoing study evaluates a new 12-week interferon-free regimen of Boehringer Ingelheim’s protease inhibitor, faldaprevir*, and non-nucleoside NS5B polymerase inhibitor, deleobuvir*, in combination with Presidio’s pan-genotypic HCV NS5A inhibitor, PPI-668*, with and without ribavirin.1,2 The trial is fully enrolled (36 patients) and to date, 97% of patients (28/29) have achieved undetectable levels of virus at week 4 of treatment, also known as rapid viral response (RVR). Additionally, 100% of patients who have completed treatment (13/13) achieved undetectable levels of virus at the end of treatment.

Continue reading this entire article:
http://www.moneylife.in/business-wire-news/investigational-interferon-free-regimen-demonstrates-undetectable-hepatitis-c-virus-in-all-patients-reaching-end-of-treatment-in-ongoing-phase-ii-trial/36829.html

22 Comments
Share
Share
Previous

Sin City’s Veiled Threat to Hepatitis C

Back to News Homepage
Next

3 Hep C Treatment Side Effects Aided by Probiotics

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.